Skip to Main Content

Author Details

David A Cooper
1974
683
100
PMIDPaper TitleJournal TitlePublished Year
37480759Understanding structure activity relationships of Good HEPES lipids for lipid nanoparticle mRNA vaccine applications.2023
36893269Divalent siRNAs are bioavailable in the lung and efficiently block SARS-CoV-2 infection.Proc Natl Acad Sci U S A2023
35477658RNAi-based modulation of IFN-γ signaling in skin.Mol Ther2022
28474534Evolution of HIV-1 Surveillance Drug Resistance Mutations Over 10 Years in New South Wales, Australia.AIDS Research and Human Retroviruses2021
34127581Broadly neutralizing antibody responses in the longitudinal primary HIV-1 infection Short Pulse Anti-Retroviral Therapy at Seroconversion cohort.AIDS2021
34916519Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza.npj Vaccines2021
31758571Sequential Helicobacter pylori eradication therapy in Myanmar; a randomized clinical trial of efficacy and tolerability.Journal of Gastroenterology and Hepatology (Australia)2020
31838857Comorbidity Medications Are Dispensed to More People Receiving Antiretroviral Therapy for HIV Compared with the General Population in Australia.AIDS Research and Human Retroviruses2020
32100684The Influence of HIV Status on the Burden and Clinical Manifestations of Gastrointestinal Pathogens in Yangon, Myanmar.American Journal of Tropical Medicine and Hygiene2020
30474916Cardiovascular disease and diabetes in HIV-positive and HIV-negative gay and bisexual men over the age of 55 years in Australia: insights from the Australian Positive & Peers Longevity Evaluation Study.HIV Medicine2019
30606134HIV treatment regimens and adherence to national guidelines in Australia: an analysis of dispensing data from the Australian pharmaceutical benefits scheme.BMC Public Health2019
30511878HIV-1 DNA Is Maintained in Antigen-Specific CD4+ T Cell Subsets in Patients on Long-Term Antiretroviral Therapy Regardless of Recurrent Antigen Exposure.AIDS Research and Human Retroviruses2019
30496881Implications of Image-Defined Risk Factors and Primary-Site Response on Local Control and Radiation Treatment Delivery in the Management of High-Risk Neuroblastoma: Is There a Role for De-escalation of Adjuvant Primary-Site Radiation Therapy?International Journal of Radiation Oncology Biology Physics2019
29538636Risk of Suicidal Behavior With Use of Efavirenz: Results from the Strategic Timing of Antiretroviral Treatment Trial.Clinical Infectious Diseases2018
28993181Towards a universal second-line fixed-dose combination ART.Lancet HIV,The2018
28447585Metabolic profiles of individuals switched to second-line antiretroviral therapy after failing standard first-line therapy for treatment of HIV-1 infection in a randomized, controlled trial.Antiviral Therapy2018
28703924Chronic kidney disease in Australian Human Immunodeficiency Virus-infected patients: Analysis of the Australian HIV Observational Database.Nephrology2018
28703491Week 96 results of the randomized, multicentre Maraviroc Switch (MARCH) study.HIV Medicine2018
30025681Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study.Lancet HIV,The2018
30343026Population-level effectiveness of rapid, targeted, high-coverage roll-out of HIV pre-exposure prophylaxis in men who have sex with men: the EPIC-NSW prospective cohort study.Lancet HIV,The2018
30143455The cascade of HIV care among key populations in Indonesia: a prospective cohort study.Lancet HIV,The2018
29901415Early Treatment of Primary HIV Infection Is Associated with Decreased Mortality.AIDS Research and Human Retroviruses2018
29676000The 2016 HIV diagnosis and care cascade in New South Wales, Australia: meeting the UNAIDS 90-90-90 targets.Journal of the International AIDS Society2018
29490635Correction: expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in new South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.BMC Public Health2018
29310898Combination ART: are two drugs as good as three?Lancet, The2018
29309346Relationship between untimed plasma lopinavir concentrations and virological outcome on second-line antiretroviral therapy.AIDS2018
29394918Expanded HIV pre-exposure prophylaxis (PrEP) implementation in communities in New South Wales, Australia (EPIC-NSW): design of an open label, single arm implementation trial.BMC Public Health2018
29704556National characteristics and trends in antiretroviral treatment in Australia can be accurately estimated using a large clinical cohort.Journal of Clinical Epidemiology2018
29381559High rates of incident diabetes and prediabetes are evident in men with treated HIV followed for 11 years.AIDS2018
29466408The clinical characteristics of adults with rheumatic heart disease in Yangon, Myanmar: An observational study.PLoS ONE2018
27815068Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-linLancet HIV,The2017
28350553Impact of Allogeneic Hematopoietic Stem Cell Transplantation on the HIV Reservoir and Immune Response in 3 HIV-Infected Individuals.J Acquir Immune Defic Syndr2017
28774293The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study.BMC Medicine2017
28346319Effect of Combination Antiretroviral Therapy on HIV-1-specific Antibody-Dependent Cellular Cytotoxicity Responses in Subtype B- and Subtype C-Infected Cohorts.Journal of acquired immune deficiency syndromes (1999)2017
28539449Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.J Virol2017
28886173Prevalence of self-reported comorbidities in HIV positive and HIV negative men who have sex with men over 55 years-The Australian Positive & Peers Longevity Evaluation Study (APPLES).PLoS ONE2017
28750936Long-acting injectable ART: next revolution in HIV?Lancet, The2017
28484447HIV-1 and SIV Predominantly Use CCR5 Expressed on a Precursor Population to Establish Infection in T Follicular Helper Cells.Frontiers in Immunology2017
28479491Long-term durability of HIV viral load suppression.Lancet HIV,The2017
28365230Mutational Correlates of Virological Failure in Individuals Receiving a WHO-Recommended Tenofovir-Containing First-Line Regimen: An International Collaboration.EBioMedicine2017
28784426Comparative efficacy and safety of second-line antiretroviral therapy for treatment of HIV/AIDS: a systematic review and network meta-analysis.Lancet HIV2017
29049331HIV dynamics linked to memory CD4+ T cell homeostasis.PLoS ONE2017
28871996Prognostic Relevance of Treatment Failure Patterns in Pediatric High-Grade Glioma: Is There a Role for a Revised Failure Classification System?Int J Radiat Oncol Biol Phys2017
29120900Reducing medical comorbidities associated with long-term HIV infection: beyond optimizing antiretroviral therapy regimens.AIDS2017
28287825Quantification of Residual Germinal Center Activity and HIV-1 DNA and RNA Levels Using Fine Needle Biopsies of Lymph Nodes During Antiretroviral Therapy.AIDS Research and Human Retroviruses2017
28257647HIV care in Yangon, Myanmar; successes, challenges and implications for policy.AIDS Research and Therapy2017
28063815Effect of immediate initiation of antiretroviral therapy on risk of severe bacterial infections in HIV-positive people with CD4 cell counts of more than 500 cells per μL: secondary outcome results from a randomised controlled trial.Lancet HIV,The2017
28063460Managing two decades of visceral leishmaniasis and HIV co-infection: a case report that illustrates the urgent research needs in the field.Sexual Health2017
27822211CD4 T Follicular Helper and IgA B Cell Numbers in Gut Biopsies from HIV-Infected Subjects on Antiretroviral Therapy Are Similar to HIV-Uninfected Individuals.Frontiers in Immunology2016
27346600Antiretroviral Resistance After First-Line Antiretroviral Therapy Failure in Diverse HIV-1 Subtypes in the SECOND-LINE Study.AIDS Research and Human Retroviruses2016
  • 1 - 50 of 683

Recommended Authors

Collaborators

The University of Melbourne at the Peter Doherty Institute for Infection and Immunity
Co-authored papers 19
IrsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol
Co-authored papers 16
Co-authored papers 14
Co-authored papers 14
Co-authored papers 11
Co-authored papers 10
Co-authored papers 9
Co-authored papers 9
Co-authored papers 8
Center for AIDS Research, University of California San Diego
Co-authored papers 8
Co-authored papers 7
University of Alabama at Birmingham
Co-authored papers 7
Co-authored papers 5
Co-authored papers 5
Co-authored papers 5
University of Washington
Co-authored papers 5
Co-authored papers 5
Co-authored papers 4
Co-authored papers 4
Chulalongkorn University
Co-authored papers 4
Division of Clinical Research, National Institutes of Allergy and Infectious Diseases
Co-authored papers 4
Brigham and Women's Hospital, Harvard Medical School
Co-authored papers 4
Ragon Institute of Mass General
Co-authored papers 4
Co-authored papers 4
Co-authored papers 4
Co-authored papers 3
Co-authored papers 3
Global Health Institute, University of Antwerp
Co-authored papers 3
Co-authored papers 3
Co-authored papers 3